Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

BACKGROUND: Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:PLoS Med
Päätekijät: Landovitz, Raphael J., Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y., Magnus, Manya, Hosseinipour, Mina C., Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A., Hendrix, Craig W., Eshleman, Susan H., Zhang, Yinfeng, Tolley, Elizabeth, Sugarman, Jeremy, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R., Margolis, David, Spreen, William R., Cohen, Myron S., McCauley, Marybeth, Eron, Joseph J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Public Library of Science 2018
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6224042/
https://ncbi.nlm.nih.gov/pubmed/30408115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1002690
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia